Royal Bank of Canada reissued their buy rating on shares of Obseva (NASDAQ:OBSV) in a research note released on Sunday, AnalystRatings.com reports.
A number of other research firms also recently weighed in on OBSV. Wedbush restated an outperform rating and set a $38.00 price target on shares of Obseva in a report on Thursday, July 18th. HC Wainwright set a $44.00 price target on shares of Obseva and gave the company a buy rating in a report on Wednesday, June 5th. ValuEngine upgraded shares of Obseva from a hold rating to a buy rating in a research note on Thursday, August 1st. Credit Suisse Group lowered their target price on shares of Obseva from $24.00 to $16.00 and set an outperform rating on the stock in a research note on Monday, July 29th. Finally, Zacks Investment Research lowered shares of Obseva from a hold rating to a sell rating in a research note on Wednesday, July 31st. One analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. Obseva currently has a consensus rating of Buy and an average price target of $27.50.
Obseva stock opened at $9.00 on Friday. The company has a market cap of $417.05 million, a P/E ratio of -4.71 and a beta of 0.91. The firm’s fifty day simple moving average is $10.02. The company has a quick ratio of 3.67, a current ratio of 3.67 and a debt-to-equity ratio of 0.02. Obseva has a 1-year low of $8.22 and a 1-year high of $19.40.
A number of large investors have recently bought and sold shares of the stock. Wedbush Securities Inc. grew its position in Obseva by 86.1% in the 1st quarter. Wedbush Securities Inc. now owns 38,790 shares of the company’s stock worth $496,000 after purchasing an additional 17,950 shares during the last quarter. Fosun International Ltd acquired a new stake in Obseva in the 1st quarter worth $2,494,000. Geode Capital Management LLC acquired a new stake in Obseva in the 4th quarter worth $159,000. Cubist Systematic Strategies LLC grew its position in Obseva by 263.6% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,272 shares of the company’s stock worth $37,000 after purchasing an additional 2,372 shares during the last quarter. Finally, Morgan Stanley grew its position in Obseva by 358.6% in the 2nd quarter. Morgan Stanley now owns 3,100 shares of the company’s stock worth $35,000 after purchasing an additional 2,424 shares during the last quarter. Institutional investors and hedge funds own 63.55% of the company’s stock.
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Read More: Blue-Chip Stocks
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.